MedTrace Logo

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

NCT03716180 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-22

No results posted yet for this study

Summary

This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.

The names study drugs involved in this study are:

* Paclitaxel (also called Taxol)
* Trastuzumab (also called Herceptin)
* Pertuzumab (also called Perjeta)

Conditions

Interventions

DRUG

Paclitaxel

Paclitaxel is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug

DRUG

Trastuzumab

Trastuzumab works by targeting the HER2/neu receptor on cancer cells

DRUG

Pertuzumab

Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death

Sponsors & Collaborators

  • Susan G. Komen Breast Cancer Foundation

    collaborator OTHER

  • Breast Cancer Research Foundation

    collaborator OTHER

  • Terri Brodeur Breast Cancer Foundation

    collaborator UNKNOWN

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Adrienne G Waks, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-05
Primary Completion
2020-10-08
Completion
2030-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03716180 on ClinicalTrials.gov